OTCMKTS:MRVFF Nuvo Pharmaceuticals (MRVFF) Stock Price, News & Analysis $0.98 0.00 (0.00%) As of 03/16/2023 Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Nuvo Pharmaceuticals Stock (OTCMKTS:MRVFF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Nuvo Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.98▼$0.9850-Day Range$0.98▼$0.9852-Week Range$0.42▼$1.25VolumeN/AAverage Volume11,250 shsMarket Capitalization$11.17 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Nuvo Pharmaceuticals, Inc. is a pharmaceutical company, which is engaged in developing innovative therapeutic pharmaceutical products. It operates through the following segments: Commercial Business, Production and Service Business, and Licensing and Royalty Business. The Commercial Business segment includes Blexten, Cambia, the canadian business for Resultz and Suvexx, and mature assets. The Production and Service Business segment supplies Pennsaid to Horizon for the U.S. market and is engaged in ongoing partnering efforts for Pennsaid. The Licensing and Royalty Business segment engages in the selling of Vimovo. The company was founded on August 22, 1983 and is headquartered in Mississauga, Canada. Read More Receive MRVFF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nuvo Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MRVFF Stock News HeadlinesHoldco Nuvo Group DG LtdMay 17, 2024 | morningstar.comMHoldco Nuvo Group DG Ltd NUVOMay 17, 2024 | morningstar.comMTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predicted it all. Even crazier, this secret accurately called every major financial event in recent history … Now it's signaling something very scary is about to hit the market again …August 26 at 2:00 AM | Weiss Ratings (Ad)Nuvo Pharmaceuticals Inc (MRVFF)May 11, 2024 | nasdaq.comNanoViricides, TC BioPharm, Holdco Nuvo among healthcare moversMay 7, 2024 | msn.comWest Pharmaceutical Services Inc WSTFebruary 2, 2024 | morningstar.comMNYMXF Nymox Pharmaceutical CorporationAugust 1, 2023 | seekingalpha.comMiravo Healthcare™ Obtains Final Order Approving Plan of ArrangementMarch 10, 2023 | businesswire.comSee More Headlines MRVFF Stock Analysis - Frequently Asked Questions How have MRVFF shares performed this year? Nuvo Pharmaceuticals' stock was trading at $0.9795 at the beginning of the year. Since then, MRVFF shares have increased by 0.0% and is now trading at $0.9795. How do I buy shares of Nuvo Pharmaceuticals? Shares of MRVFF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today8/26/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:MRVFF CIKN/A Webwww.nuvopharmaceuticals.com Phone(905) 673-6980Fax905-673-1842Employees100Year FoundedN/AProfitability EPS (Trailing Twelve Months)($0.12) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$25.70 million Net Margins20.88% Pretax Margin25.58% Return on Equity-1,996.22% Return on Assets14.25% Debt Debt-to-Equity Ratio9.97 Current Ratio2.11 Quick Ratio1.77 Sales & Book Value Annual Sales$54.98 million Price / Sales0.20 Cash Flow$0.09 per share Price / Cash Flow11.09 Book Value($0.80) per share Price / Book-1.22Miscellaneous Outstanding Shares11,400,000Free Float10,602,000Market Cap$11.17 million OptionableNot Optionable Beta0.98 Social Links 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (OTCMKTS:MRVFF) was last updated on 8/26/2025 by MarketBeat.com Staff From Our Partners“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredCover all your expenses with just $118,000 invested?Generate up to $5,000/month with 10X less money? That's what every financial advisor tells you. But I just ...Investors Alley | SponsoredFed Decision Warning: How to Protect Your Wealth Before September 30th On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the...American Alternative | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump’s national nightmare is hereWhile the headlines focus on global conflicts, there’s a very different crisis brewing at home. Washington has...Porter & Company | SponsoredIt’s game over for Central BanksCentral banks are losing control. Inflation isn’t fixed, debt is exploding, and stocks have never looked more ...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuvo Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nuvo Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.